

Statement on Ethical Use of Prescription Opioids

Siegfried is an integrated supplier for the pharmaceutical industry with production facilities located in Switzerland, Germany, Malta, France, China and the USA. Among other manufacturing related services, Siegfried produces and offers a broad portfolio of drug substances, where as part of the portfolio are controlled substances being used by Siegfried's customers to manufacture opioid drug products, including opioid agonists and/or antagonists.

Siegfried does not manufacture, distribute or sell opioid drug products in the USA. However, as a manufacturer of controlled substances that are used for the production of opioid drug products, Siegfried is aware of its special ethical responsibility. Siegfried strives to ensure that all its controlled substances are not misused and strongly objects to any use of its products other than for approved ethical purposes as set forth in its Code of Business Conduct.

In accordance with applicable laws and regulations, Siegfried implemented and adheres to strict and comprehensive internal policies and procedures on security and safety in the manufacture, storing, transportation and handling of all controlled substances under its control. All of Siegfried's employees handling such controlled substances have undergone training as required by regulatory agencies on these policies and procedures. Siegfried is committed to ensure that its customers and other business partners endorse and respect Siegfried's ethical standards by way of appropriate contractual commitments and other measures.

Siegfried, as a service provider for the pharmaceutical industry, endorses the initiatives and efforts of its customers, the US government, and the FDA as well as other regulatory agencies in combatting the non-medical use of prescription opioids. We support the expanded use of Medication Assisted Treatment (MAT), including opioid treatment programs (OTPs), which combines behavioral therapy and medications to treat prescription drugs addiction. Medication commonly used in MAT is based on the drug substances Methadone, Naltrexone and Buprenorphine, which are offered by and available from Siegfried.

Moreover, Siegfried provides development and manufacture related services for its customer's drug products that are intended for the treatment of opioid dependence, such as, but not limited to, abuse-deterrent formulations.

Issued by

Siegfried Holding AG
Siegfried Integrity Office
Edition 2024

Contact

Siegfried Holding AG
Untere Brühlstrasse 4
4800 Zofingen

Switzerland
integrity@siegfried.ch
www.siegfried.ch